FcγR: The key to optimize therapeutic antibodies?

Critical Reviews in Oncology/Hematology

Volumn 62, Issue 1, 2007, Pages 26-33

  Sibéril, Sophie ^a   Dutertre, Charles Antoine ^a,b   Fridman, Wolf Herman ^a   Teillaud, Jean Luc ^a  

^a INSERM   (France)

^b Departement Recherche   (France)

Author keywords

Fc receptors; Optimization of monoclonal antibodies; Therapeutic antibodies

Indexed keywords

ALEMTUZUMAB; FC RECEPTOR; IMMUNOGLOBULIN; MONOCLONAL ANTIBODY; RECEPTOR SUBTYPE; RITUXIMAB; TRASTUZUMAB; LEUKOCYTE ANTIGEN;

HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; NONHODGKIN LYMPHOMA; NONHUMAN; REVIEW; ANIMAL; ANTIBODY SPECIFICITY; CHEMISTRY; DRUG DELIVERY SYSTEM; GENETICS; IMMUNOLOGY; METHODOLOGY;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; ANTIGENS, CD; DRUG DELIVERY SYSTEMS; HUMANS; RECEPTORS, IGG;

EID: 33847399072     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2006.12.003     Document Type: Review

References (66)

1. Gessner J.E., Heiken H., Tamm A., and Schmidt R.E. The IgG Fc receptor family. Ann Hematol 76 (1998) 231-248
2. Peltz G., Frederick K., Anderson C.L., and Peterlin B.M. Characterization of the human monocyte high affinity Fc receptor (hu FcRI). Mol Immunol 25 (1988) 243-250
3. Ernst L.K., van de Winkel J.G., Chiu I.M., and Anderson C.L. Three genes for the human high affinity Fc receptor for IgG (Fc gamma RI) encode four distinct transcription products. J Biol Chem 267 (1992) 15692-15700
4. Salmon J.E., Millard S.S., Brogle N.L., and Kimberly R.P. Fc gamma receptor IIIb enhances Fc gamma receptor IIa function in an oxidant-dependent and allele-sensitive manner. J Clin Invest 95 (1995) 2877-2885
5. Cassel D.L., Keller M.A., Surrey S., et al. Differential expression of Fc gamma RIIA, Fc gamma RIIB and Fc gamma RIIC in hematopoietic cells: analysis of transcripts. Mol Immunol 30 (1993) 451-460
6. Phillips N.E., and Parker D.C. Fc-dependent inhibition of mouse B cell activation by whole anti-mu antibodies. J Immunol 130 (1983) 602-606
7. Amigorena S., Bonnerot C., Drake J.R., et al. Cytoplasmic domain heterogeneity and functions of IgG Fc receptors in B lymphocytes. Science 256 (1992) 1808-1812
8. Diamond B., and Yelton D.E. A new Fc receptor on mouse macrophages binding IgG3. J Exp Med 153 (1981) 514-519
9. Teillaud J.L., Diamond B., Pollock R.R., Fajtova V., and Scharff M.D. Fc receptors on cultured myeloma and hybridoma cells. J Immunol 134 (1985) 1774-1779
10. Gavin A.L., Tan P.S., and Hogarth P.M. Gain-of-function mutations in FcgammaRI of NOD mice: implications for the evolution of the Ig superfamily. EMBO J 17 (1998) 3850-3857
11. Mechetina L.V., Najakshin A.M., Alabyev B.Y., Chikaev N.A., and Taranin A.V. Identification of CD16-2, a novel mouse receptor homologous to CD16/Fc gamma RIII. Immunogenetics 54 (2002) 463-468
12. Nimmerjahn F., Bruhns P., Horiuchi K., and Ravetch J.V. FcgammaRIV: a novel FcR with distinct IgG subclass specificity. Immunity 23 (2005) 41-51
13. Ravetch J.V., and Bolland S. IgG Fc receptors. Annu Rev Immunol 19 (2001) 275-290
14. Takai T., Li M., Sylvestre D., Clynes R., and Ravetch J.V. FcR gamma chain deletion results in pleiotrophic effector cell defects. Cell 76 (1994) 519-529
15. Clynes R., Takechi Y., Moroi Y., Houghton A., and Ravetch J.V. Fc receptors are required in passive and active immunity to melanoma. Proc Natl Acad Sci USA 95 (1998) 652-656
16. Hazenbos W.L., Heijnen I.A., Meyer D., et al. Murine IgG1 complexes trigger immune effector functions predominantly via Fc gamma RIII (CD16). J Immunol 161 (1998) 3026-3032
17. Meyer D., Schiller C., Westermann J., et al. FcgammaRIII (CD16)-deficient mice show IgG isotype-dependent protection to experimental autoimmune hemolytic anemia. Blood 92 (1998) 3997-4002
18. Wernersson S., Karlsson M.C., Dahlstrom J., Mattsson R., Verbeek J.S., and Heyman B. IgG-mediated enhancement of antibody responses is low in Fc receptor gamma chain-deficient mice and increased in Fc gamma RII-deficient mice. J Immunol 163 (1999) 618-622
19. Hazenbos W.L., Gessner J.E., Hofhuis F.M., et al. Impaired IgG-dependent anaphylaxis and Arthus reaction in Fc gamma RIII (CD16) deficient mice. Immunity 5 (1996) 181-188
20. Takai T., Ono M., Hikida M., Ohmori H., and Ravetch J.V. Augmented humoral and anaphylactic responses in Fc gamma RII-deficient mice. Nature 379 (1996) 346-349
21. Karlsson M.C., Wernersson S., Diaz de Stahl T., Gustavsson S., and Heyman B. Efficient IgG-mediated suppression of primary antibody responses in Fcgamma receptor-deficient mice. Proc Natl Acad Sci USA 96 (1999) 2244-2249
22. Karlsson M.C., Getahun A., and Heyman B. FcgammaRIIB in IgG-mediated suppression of antibody responses: different impact in vivo and in vitro. J Immunol 167 (2001) 5558-5564
23. Bolland S., and Ravetch J.V. Spontaneous autoimmune disease in Fc(gamma)RIIB-deficient mice results from strain-specific epistasis. Immunity 13 (2000) 277-285
24. Bolland S., Yim Y.S., Tus K., Wakeland E.K., and Ravetch J.V. Genetic modifiers of systemic lupus erythematosus in FcgammaRIIB(-/-) mice. J Exp Med 195 (2002) 1167-1174
25. Jiang Y., Hirose S., Sanokawa-Akakura R., et al. Genetically determined aberrant down-regulation of FcgammaRIIB1 in germinal center B cells associated with hyper-IgG and IgG autoantibodies in murine systemic lupus erythematosus. Int Immunol 11 (1999) 1685-1691
26. Pritchard N.R., Cutler A.J., Uribe S., Chadban S.J., Morley B.J., and Smith K.G. Autoimmune-prone mice share a promoter haplotype associated with reduced expression and function of the Fc receptor FcgammaRII. Curr Biol 10 (2000) 227-230
27. Xiu Y., Nakamura K., Abe M., et al. Transcriptional regulation of Fcgr2b gene by polymorphic promoter region and its contribution to humoral immune responses. J Immunol 169 (2002) 4340-4346
28. Kalergis A.M., and Ravetch J.V. Inducing tumor immunity through the selective engagement of activating Fcgamma receptors on dendritic cells. J Exp Med 195 (2002) 1653-1659
29. Dhodapkar K.M., Kaufman J.L., Ehlers M., et al. Selective blockade of inhibitory Fcgamma receptor enables human dendritic cell maturation with IL-12p70 production and immunity to antibody-coated tumor cells. Proc Natl Acad Sci USA 102 (2005) 2910-2915
30. Boruchov A.M., Heller G., Veri M.C., Bonvini E., Ravetch J.V., and Young J.W. Activating and inhibitory IgG Fc receptors on human DCs mediate opposing functions. J Clin Invest 115 (2005) 2914-2923
31. Tax W.J., Hermes F.F., Willems R.W., Capel P.J., and Koene R.A. Fc receptors for mouse IgG1 on human monocytes: polymorphism and role in antibody-induced T cell proliferation. J Immunol 133 (1984) 1185-1189
32. Takai T. Roles of Fc receptors in autoimmunity. Nat Rev Immunol 2 (2002) 580-592
33. Binstadt B.A., Geha R.S., and Bonilla F.A. IgG Fc receptor polymorphisms in human disease: implications for intravenous immunoglobulin therapy. J Allergy Clin Immunol 111 (2003) 697-703
34. Su K., Wu J., Edberg J.C., et al. A promoter haplotype of the immunoreceptor tyrosine-based inhibitory motif-bearing FcgammaRIIb alters receptor expression and associates with autoimmunity. I. Regulatory FCGR2B polymorphisms and their association with systemic lupus erythematosus. J Immunol 172 (2004) 7186-7191
35. Su K., Li X., Edberg J.C., Wu J., Ferguson P., and Kimberly R.P. A promoter haplotype of the immunoreceptor tyrosine-based inhibitory motif-bearing FcgammaRIIb alters receptor expression and associates with autoimmunity. II. Differential binding of GATA4 and Yin-Yang1 transcription factors and correlated receptor expression and function. J Immunol 172 (2004) 7192-7199
36. Nimmerjahn F., and Ravetch J.V. Fcgamma receptors: old friends and new family members. Immunity 24 (2006) 19-28
37. Clynes R.A., Towers T.L., Presta L.G., and Ravetch J.V. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med 6 (2000) 443-446
38. Zhang Z., Zhang M., Goldman C.K., Ravetch J.V., and Waldmann T.A. Effective therapy for a murine model of adult T-cell leukemia with the humanized anti-CD52 monoclonal antibody, Campath-1H. Cancer Res 63 (2003) 6453-6457
39. Zhang M., Zhang Z., Garmestani K., et al. Activating Fc receptors are required for antitumor efficacy of the antibodies directed toward CD25 in a murine model of adult t-cell leukemia. Cancer Res 64 (2004) 5825-5829
40. Uchida J., Hamaguchi Y., Oliver J.A., et al. The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy. J Exp Med 199 (2004) 1659-1669
41. Cartron G., Dacheux L., Salles G., et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 99 (2002) 754-758
42. Weng W.K., and Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 21 (2003) 3940-3947
43. Farag S.S., Flinn I.W., Modali R., Lehman T.A., Young D., and Byrd J.C. Fc gamma RIIIa and Fc gamma RIIa polymorphisms do not predict response to rituximab in B-cell chronic lymphocytic leukemia. Blood 103 (2004) 1472-1474
44. Lin T.S., Flinn I.W., Modali R., et al. FCGR3A and FCGR2A polymorphisms may not correlate with response to alemtuzumab in chronic lymphocytic leukemia. Blood 105 (2005) 289-291
45. Kazatchkine M.D., and Kaveri S.V. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med 345 (2001) 747-755
46. Debre M., Bonnet M.C., Fridman W.H., et al. Infusion of Fc gamma fragments for treatment of children with acute immune thrombocytopenic purpura. Lancet 342 (1993) 945-949
47. Bussel J.B. Fc receptor blockade and immune thrombocytopenic purpura. Semin Hematol 37 (2000) 261-266
48. Samuelsson A., Towers T.L., and Ravetch J.V. Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science 291 (2001) 484-486
49. Kaneko Y., Nimmerjahn F., Madaio M.P., and Ravetch J.V. Pathology and protection in nephrotoxic nephritis is determined by selective engagement of specific Fc receptors. J Exp Med 203 (2006) 789-797
50. Siragam V., Crow A.R., Brinc D., Song S., Freedman J., and Lazarus A.H. Intravenous immunoglobulin ameliorates ITP via activating Fc gamma receptors on dendritic cells. Nat Med 12 (2006) 688-692
51. Hamerman J.A., and Lanier L.L. Inhibition of immune responses by ITAM-bearing receptors. Sci STKE 2006 (2006) re1
52. Akilesh S., Petkova S., Sproule T.J., Shaffer D.J., Christianson G.J., and Roopenian D. The MHC class I-like Fc receptor promotes humorally mediated autoimmune disease. J Clin Invest 113 (2004) 1328-1333
53. Shields R.L., Namenuk A.K., Hong K., et al. High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R. J Biol Chem 276 (2001) 6591-6604
54. Lazar G.A., Dang W., Karki S., et al. Engineered antibody Fc variants with enhanced effector function. Proc Natl Acad Sci USA 103 (2006) 4005-4010
55. Radaev S., Motyka S., Fridman W.H., Sautes-Fridman C., and Sun P.D. The structure of a human type III Fcgamma receptor in complex with Fc. J Biol Chem 276 (2001) 16469-16477
56. Radaev S., and Sun P.D. Recognition of IgG by Fcgamma receptor. The role of Fc glycosylation and the binding of peptide inhibitors. J Biol Chem 276 (2001) 16478-16483
57. Krapp S., Mimura Y., Jefferis R., Huber R., and Sondermann P. Structural analysis of human IgG-Fc glycoforms reveals a correlation between glycosylation and structural integrity. J Mol Biol 325 (2003) 979-989
58. Umana P., Jean-Mairet J., Moudry R., Amstutz H., and Bailey J.E. Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity. Nat Biotechnol 17 (1999) 176-180
59. Davies J., Jiang L., Pan L.Z., LaBarre M.J., Anderson D., and Reff M. Expression of GnTIII in a recombinant anti-CD20 CHO production cell line: expression of antibodies with altered glycoforms leads to an increase in ADCC through higher affinity for FC gamma RIII. Biotechnol Bioeng 74 (2001) 288-294
60. Shinkawa T., Nakamura K., Yamane N., et al. The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. J Biol Chem 278 (2003) 3466-3473
61. Siberil S., de Romeuf C., Bihoreau N., et al. Selection of a human anti-RhD monoclonal antibody for therapeutic use: impact of IgG glycosylation on activating and inhibitory Fc gamma R functions. Clin Immunol 118 (2006) 170-179
62. Shields R.L., Lai J., Keck R., et al. Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity. J Biol Chem 277 (2002) 26733-26740
63. Niwa R., Hatanaka S., Shoji-Hosaka E., et al. Enhancement of the antibody-dependent cellular cytotoxicity of low-fucose IgG1 Is independent of FcgammaRIIIa functional polymorphism. Clin Cancer Res 10 (2004) 6248-6255
64. Niwa R., Sakurada M., Kobayashi Y., et al. Enhanced natural killer cell binding and activation by low-fucose IgG1 antibody results in potent antibody-dependent cellular cytotoxicity induction at lower antigen density. Clin Cancer Res 11 (2005) 2327-2336
65. Mori K., Kuni-Kamochi R., Yamane-Ohnuki N., et al. Engineering Chinese hamster ovary cells to maximize effector function of produced antibodies using FUT8 siRNA. Biotechnol Bioeng 88 (2004) 901-908
66. Yamane-Ohnuki N., Kinoshita S., Inoue-Urakubo M., et al. Establishment of FUT8 knockout Chinese hamster ovary cells: an ideal host cell line for producing completely defucosylated antibodies with enhanced antibody-dependent cellular cytotoxicity. Biotechnol Bioeng 87 (2004) 614-622